Dr Kylie Quinn is RMIT University Vice-Chancellor's Research Fellow and leads the new Ageing and Immunotherapies Group developing ways to improve immune responses in older individuals during infection, vaccination, and new cell-based therapies such as chimeric antigen receptor T cell therapy (CTT). Previously, she trained at the Vaccine Research Center (VRC), NIAID/NIH, USA, where she defined the mechanism of action for several novel vaccines and provided key pre-clinical data for Ebola vaccine selection by the World Health Organization in 2014.
Dr Kylie Quinn is RMIT University Vice-Chancellor's Research Fellow and leads the new Ageing and Immunotherapies Group developing ways to improve immune responses in older individuals during infection, vaccination, and new cell-based therapies such as chimeric antigen receptor T cell therapy (CTT). Previously, she trained at the Vaccine Research Center (VRC), NIAID/NIH, USA, where she defined the mechanism of action for several novel vaccines and provided key pre-clinical data for Ebola vaccine selection by the World Health Organization in 2014.